Person: ERGELEN, RABİA
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
ERGELEN
First Name
RABİA
Name
11 results
Search Results
Now showing 1 - 10 of 11
Publication Open Access Is renal abscess still a problem?(MARMARA UNIV, FAC MEDICINE, 2021-01-26) ALPAY, HARİKA; Sak, Mehtap; Gokce, Ibrahim; Cicek, Neslihan; Guven, Sercin; Ergelen, Rabia; Yildiz, Nurdan; Alpay, HarikaRenal abscess, the accumulation of infected fluid in the kidney, is a rare condition seen in children as well as adults. It leads to long term hospital admission and antibiotic use. Early diagnosis is an important factor in the outcome of renal abscess because the management may differ. Urinalysis test results and radiologic imaging findings of the patients who are admitted to hospital with complaints of fever, vomiting, abdominal pain or flank pain are important for the early diagnosis. Undertreated cases have high risk for renal scar formation. In this paper, we aim to present three pediatric patients, who showed the complication of renal abscess and were treated with long term antibiotic use without a need for surgical drainage.Publication Open Access Common femoral vein thickness measurement as a diagnostic test in incomplete behcet's disease(2022-06-01) ALİBAZ ÖNER, FATMA; ERGELEN, RABİA; ERGUN, SAFİYE ATLAS TÜLİN; DİRESKENELİ, RAFİ HANER; Alibaz-Oner F., Ergelen R., Temiz F., Agackiran S. K. , Soydemir E., Ergun T., DİRESKENELİ R. H.Publication Open Access Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease(NATURE RESEARCH, 2021-02) ÖZEN, AHMET OĞUZHAN; Ozen, Ahmet; Kasap, Nurhan; Vujkovic-Cvijin, Ivan; Apps, Richard; Cheung, Foo; Karakoc-Aydiner, Elif; Akkelle, Bilge; Sari, Sinan; Tutar, Engin; Ozcay, Figen; Uygun, Dilara Kocacik; Islek, Ali; Akgun, Gamze; Selcuk, Merve; Sezer, Oya Balci; Zhang, Yu; Kutluk, Gunsel; Topal, Erdem; Sayar, Ersin; Celikel, Cigdem; Houwen, Roderick H. J.; Bingol, Aysen; Ogulur, Ismail; Eltan, Sevgi Bilgic; Snow, Andrew L.; Lake, Camille; Fantoni, Giovanna; Alba, Camille; Sellers, Brian; Chauvin, Samuel D.; Dalgard, Clifton L.; Harari, Olivier; Ni, Yan G.; Wang, Ming-Dauh; Devalaraja-Narashimha, Kishor; Subramanian, Poorani; Ergelen, Rabia; Artan, Reha; Guner, Sukru Nail; Dalgic, Buket; Tsang, John; Belkaid, Yasmine; Ertem, Deniz; Baris, Safa; Lenardo, Michael J.CHAPLE disease is a lethal syndrome caused by genetic loss of the complement regulatory protein CD55. Lenardo, Ozen and their colleagues report that blockade of C5 complement activation in a small cohort of pediatric patients with CHAPLE disease reduced gastrointestinal pathology and restored their immunity and growth. Complement hyperactivation, angiopathic thrombosis and protein-losing enteropathy (CHAPLE disease) is a lethal disease caused by genetic loss of the complement regulatory protein CD55, leading to overactivation of complement and innate immunity together with immunodeficiency due to immunoglobulin wasting in the intestine. We report in vivo human data accumulated using the complement C5 inhibitor eculizumab for the medical treatment of patients with CHAPLE disease. We observed cessation of gastrointestinal pathology together with restoration of normal immunity and metabolism. We found that patients rapidly renormalized immunoglobulin concentrations and other serum proteins as revealed by aptamer profiling, re-established a healthy gut microbiome, discontinued immunoglobulin replacement and other treatments and exhibited catch-up growth. Thus, we show that blockade of C5 by eculizumab effectively re-establishes regulation of the innate immune complement system to substantially reduce the pathophysiological manifestations of CD55 deficiency in humans.Publication Open Access ASSESSMENT OF FEMORAL VEIN WALL THICKNESS WITH DOPPLER US AS A DIAGNOSTIC TOOL FOR BEHCET'S DISEASE(BMJ PUBLISHING GROUP, 2020-06) ALİBAZ ÖNER, FATMA; Alibaz-Oner, F.; Ergelen, R.; Yildiz, Y.; Yazici, A.; Aldag, M.; Cefle, A.; Artim-Esen, B.; Mumcu, G.; Ergun, T.; Direskeneli, H.Publication Open Access Duration of ciprofloxacin use is important in the development of abdominal aortic aneurysm in a rat model(2022-11-01) ÖZYILMAZ YAY, NAGEHAN; ERGELEN, RABİA; AKAKIN, DİLEK; GÜLHAN, REZZAN; Çulpan Y., Keçeci İ., Sandıkçı İ., Gökçe Ş., Göker H., ÖZYILMAZ YAY N., ERGELEN R., AKAKIN D., GÜLHAN R.BACKGROUND: Recent findings suggest that fluoroquinolones, most prescribed antibiotic to treat various infections, have increased abdominal aortic aneurysm formation. We aimed to investigate the relation of the development of abdominal aortic aneurysm and the duration of ciprofloxacin use. METHODS: Male Sprague-Dawley rats were divided into 2 groups to administer saline to the control groups and CaCl2 to the aneurysm groups. These groups were then divided into 3 subgroups: intraperitoneal saline, ciprofloxacin for 2 weeks, and ciprofloxacin for 4 weeks. At the end of 4 weeks, the diameter of abdominal aorta was determined by ultrasonography and animals were sacrificed to obtain abdominal aorta specimens. Elastic fiber fracture, tunica media layer thickness, and aortic tissue damage were evaluated histologically. RESULTS: Aortic diameter of control-saline (2.15 mm ± 0.06), control-2 weeks (2.25 mm ± 0.06), and control-4 weeks (3.31 mm ± 0.09) ciprofloxacin groups was significantly different (P .05). CONCLUSION: The study showed that ciprofloxacin caused injury in the aortic wall but not a significant change in the thickness of the aortic tunica media layer. The duration of ciprofloxacin use was important in the development of aneurysm and aneurysm severity.Publication Metadata only Outcomes of Pediatric Fistulising Perianal Crohn's Disease(AVES, 2021) ERTEM ŞAHİNOĞLU, DENİZ; Akkelle, Bilge S.; Sengul, Ozlem K.; Volkan, Burcu; Tutar, Engin; Ergelen, Rabia; Yardimci, Samet; Ertem, DenizBackground: Perianal disease is reported more widely in pediatric Crohn patients than in the past, and hos been stated as an independent modifier of the disease behavior. In this study, we aimed to analyze the clinical characteristics and outcomes of fistulising perianal Crohn's disease (fpCD) in the pediatric age group. Methods: A total number of 149 children with an established diagnosis of inflammatory bowel disease who have been diagnosed before 18 years of age and followed in our tertiary center were revised. Clinical, endoscopic, laboratory, and radiologic data of 50 patients with CD, who had at least 18 months follow-up data, were compiled. Results: Of 50 patients, 26 (52%) were diagnosed as fpCD (38% at onset). More than half of the patients without any notable external orifices around the perianal area were diagnosed as fpCD by an magnetic resonance imaging (MRI). Pediatric fpCD patients hod a higher disease activity score and platelet count, lower serum albumin level, and a higher rate of granuloma in the biopsy samples, compared with non-fistulising patients. A considerably high rate of surgical interventions (i.e., seton placement 46% and abscess drainage 15%) was performed in combination with infiiximab. Conclusion: Fistulising perianal Crohn's disease seems to be more common than previously reported in the pediatric age group. A severe course of the disease might serve as a warning for the development of fpCD. A careful physical examination and use of perianal MRI with a high index of suspicion may increase the likelihood of fistula detection, hence may change the treatment strategy.Publication Metadata only A rare case of primary rectal choriocarcinoma and review of the literature(SAGE PUBLICATIONS LTD, 2020) ATICI, ALİ EMRE; Telli, Tugba A.; Demircan, Nazim C.; Alan, Ozkan; Tuylu, Tugba B.; Arikan, Rukiye; Ercelep, Ozlem; Atici, Ali E.; Ergelen, Rabia; Seven, Ipek E.; Babacan, Nalan A.; Kaya, Serap; Dane, Faysal; Yumuk, Perran FuldenIntroduction Primary choriocarcinoma of the colon is an extremely rare neoplasm which has a poor prognosis. Only 18 cases have been previously reported in English medical literature. Here we present a case of primary rectal choriocarcinoma with a good response to chemotherapy and review the literature on this uncommon tumor. Case report A 36-year-old woman presented with abdominal pain and vaginal bleeding. Abdominal magnetic resonance imaging revealed 6.9 x 5.3 x 6.4 cm hypervascular mass posterior to uterus very close to rectum. Beta-human chorionic gonadotropin (beta-hCG) level was markedly elevated. Low anterior resection of the rectum with lymph node dissection and total abdominal hysterectomy with bilateral salpingo-oophorectomy were performed. Pathologic diagnosis was reported as colonic choriocarcinoma with a focal component of adenocarcinoma. Post-operative magnetic resonance imaging detected multiple metastatic lesions throughout the liver. The patient was treated with systemic chemotherapy using bleomycin, etoposide and cisplatin (BEP protocol). After three cycles, beta-hCG level decreased to normal and magnetic resonance imaging showed regression of liver metastasis. However, the patient died of respiratory failure due to bleomycin toxicity and pneumonia accompanied by rapid disease progression. Discussion This is an extremely rare case of primary rectal choriocarcinoma. Due to poor prognosis of the disease, it seems very important to start prompt treatment to improve patient's survival.Publication Metadata only PREDICTORS AND SEVERITY OF POST-THROMBOTIC SYNDROME IN VASCULAR BEHCET'S DISEASE: RETROSPECTIVE MULTICENTER STUDY(BMJ PUBLISHING GROUP, 2020) ALİBAZ ÖNER, FATMA; Aksoy, A.; Colak, S.; Yagiz, B.; Seniz, B. N.; Omma, A.; Yildiz, Y.; Atas, N.; Ilgin, C.; Sari, A.; Erden, A.; Karadag, O.; Dalkilic, E.; Bolca, N.; Onur, M. N.; Ergelen, R.; Direskeneli, H.; Alibaz-Oner, F.Publication Metadata only Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib(SAGE PUBLICATIONS LTD, 2020) ÇİÇEK, FURKAN CUMA; Demircan, Nazim C.; Alan, Ozkan; Tuylu, Tugba Basoglu; Telli, Tugba Akin; Arikan, Rukiye; Cicek, Furkan C.; Ercelep, Ozlem; Ozturk, Mehmet A.; Cetin, Ilknur Alsan; Ergelen, Rabia; Tinay, Ilker; Babacan, Nalan Akgul; Kaya, Serap; Dane, Faysal; Yumuk, Perran F.Background Anti-angiogenic tyrosine kinase inhibitors, sunitinib and pazopanib, have proven efficacy in advanced renal cell carcinoma, with specific adverse events occurring during treatment process. Comorbidities can reflect functional status and have prognostic value in oncology patients. We aimed to assess the association of the Charlson Comorbidity Index with severe toxicities and mortality in renal cell carcinoma cases treated with front-line sunitinib or pazopanib. Methods Files of locally advanced and metastatic renal cell carcinoma patients who received first-line sunitinib or pazopanib were retrospectively examined. Charlson Comorbidity Index of each patient was calculated. Patients were also stratified into Memorial Sloan-Kettering Cancer Center risk groups. Predictors of dose-limiting toxicity were evaluated with binomial logistic regression analysis. Univariate and multivariate Cox regression models were utilized to determine prognostic factors for survival. Results The study included 102 patients, 64 were treated with first-line sunitinib and 38 with pazopanib. In 42 patients (41.9%), Charlson Comorbidity Index was 9 or more. Dose-limiting toxicities were significantly more frequent in Charlson Comorbidity Index >= 9 group (69% vs. 40%, p = 0.004), and Charlson Comorbidity Index independently predicted dose-limiting toxicity (Hazard ratio (HR) = 4.30, p = 0.002). After adjusting for other variables, a Charlson Comorbidity Index of >= 9 is also a significant prognostic factor for progression-free (HR = 1.76, p = 0.02) and overall survival (HR = 1.75, p = 0.03). Conclusions Charlson Comorbidity Index may be a valuable method to estimate prognosis and optimize therapy in patients with advanced renal cell carcinoma receiving first-line sunitinib or pazopanib.Publication Open Access Prognostic value of common femoral vein wall thickness in behcet disease: a prospective follow-up study(2022-06-01) ERGELEN, RABİA; ERGUN, SAFİYE ATLAS TÜLİN; DİRESKENELİ, RAFİ HANER; ALİBAZ ÖNER, FATMA; Abacar K., Ergelen R., Temiz F., Yildiz Y., Ergun T., DİRESKENELİ R. H. , Alibaz-Oner. F.